Rahul Sharma (Editor)

Teprotumumab

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Type  Whole antibody
Target  IGF-1R
CAS Number  1036734-93-6
Source  Human
ATC code  none
ChemSpider  none

Teprotumumab (RG-1507) is an experimental human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R.

Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer and sarcoma. Although results of phase I and early phase II trials showed promise, research for these indications were discontinued in 2009 by Roche. Phase II trials still in progress were allowed to complete, as the development was halted due to business prioritization rather than safety concerns.

Teprotumumab was subsequently licensed to River Vision Development Corporation in 2012 for research in the treatment of ophthalmic conditions. It is in phase II trials for Graves' ophthalmopathy and phase I for diabetic macular edema. It was granted Orphan Drug Status by the FDA for Graves' ophthalmopathy.

References

Teprotumumab Wikipedia


Topics
 
B
i
Link
H2
L